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HISTORICAL PATTERNS OF GLOBAL HEALTH SPENDING
Over the past century medical technology has provided bold gains extending human longevity for
almost several decades in most welfare economies worldwide. These public health victories came
at the cost of huge increase in health spending. The USA, the largest health care market where
total health expenditure (THE) grew from 4% of GDP to 15%, may serve as an example of such
changes. The secular trend consisting of rising wages and incomes constitutes major factor in the
rising resources dedicated to the medical care. Business cycle booms and recessions affected health
care spending slowly and with a significant lag. In this sense health expenditures should not be
compared to short term, quarterly or yearly fluctuations in Gross Domestic Product (GDP) but
correlates well to “smoothed” income over the previous 3–6 years (Getzen, 1990).
Growth of health expenditure is driven by several underlying issues: population birth rates,
per-capita income, inflation and so called “excess growth” that is mostly explained by medical
technology advances or increased patient demand for services. This “excess growth” is responsible
for raising the share of health care in national GDP, and thus challenging fiscal sustainability.
Evidence of excess growth is seen in health insurance premiums that persistently rise faster than tax
revenues or wages. Isolated excess cost growth was the key underlying reason for the surmountable
surge in health care costs visible in the United States since the late 1950s. Unlike the contemporary
post WWII era, previous historical records testify of stable medical costs of about 4% of GDP from
1929 to the late 1950s. U.S. Census records of employment in clinical medicine and published
consumer expenditure evidence from 1850–1950 show that these costs were mostly keeping pace
with wages. If they were slightly exceeding wages it was only about 0.5% annually thus it took more
than a century for them to double, much slower than the quadrupling from 1960 to 2000 (Getzen,
2000). Major causes of such a sudden rise in health expenditures were huge economic development,
distinctively extended longevity, control of contagious diseases, rising availability of income used to
fund research in medicine, effective financing instruments, and ultimately significant discoveries in
medical technologies that supported public willingness for further investment into potential novel
biological drugs, implants, robotic surgery, radiation therapy, organ transplants, and other wonder
technologies (Getzen, 2014).
With several decades delay, due to dissemination of knowledge and improved societal welfare
across the globe, similar developments began at the far smaller scale in a large number of low
and middle income world economies. Among 160 such nations in the beginning of 1990s long
term trends have revealed 16 countries which made greater investments in health care and its core
outcomes than most comparable nations. These countries were described by Goldman-Sachs as the
world’s leading emerging markets. They are listed under the acronyms BRICS (Brazil, Russia, India,
China, South Africa) and Next Eleven (N-11: Bangladesh, Egypt, Indonesia, Iran, South Korea,
Mexico, Nigeria, Pakistan, the Philippines, Turkey, and Vietnam). This ongoing evolution will most
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likely shape the appearance of global demand and supply of
medical services in XXI century and we believe that therefore it
deserves closer examination.
GROWTH OF HEALTH CARE SPENDING IN
LOW AND MIDDLE INCOME COUNTRIES
SINCE 1995
The last two decades have been particularly dynamic due to
ending the Cold War and accelerated pace of globalization.
Contemporary evolution was promising for most nations
with average world THE rising from 5.7 to 6.8% GDP
[a 19.3% gain or approximately 1% yearly increase over
19 years (Table 1)]. Since 1995 World Health Organization
(WHO) has established and disseminated National Health
Accounts (NHA) system worldwide. These efforts allowed
reliable international comparison of financial flows among
national health systems with diverse historical legacies. The
World Bank (WB) introduced the measure of gross national
income (GNI) classification of countries in 1987 with their Atlas
method and GNI per capita indexed in US$ currency (World
Bank Income Groups, 2015). Availability of national income per
capita strongly influences health expenditure. The correlation
is straightforward with a secular trend visible in long time
horizons inmost world regions.We applied historical lists of WB
income classification to reveal patterns in global health spending.
Participation of 160 low andmiddle income countries (as defined
by WB in 1995) in global health spending (in million const. 2005
$US) was 10.7%. Nineteen years later the world was a much
different place. Global welfare of nations recorded bold increases
while 23 countries crossed the WB threshold for high income
economies. The remaining 137 low and middle income countries
(as defined by WB in 2013) were now spending 14.6% of global
THE expressed in millions of constant 2005 $US. The landscape
of national medical spending has evolved in favor of developing
regions. The 160 countries classified as low and middle by WB in
1995 grew from 26.1% of global THE in 1995 to 39.7% in 2013.
While high income economies still dominate the global landscape
of medical spending, the growth of emerging economies has
reduced their share of the total.
CAUSES OF CHANGES AND LEADERSHIP
OF BRICS + NEXT-11 EMERGING NATIONS
Jim O’Neil’s grouping of BRICs was driven primarily designating
those whose nominal and purchase power parity (PPP) adjusted
GDP growth rates significantly outpaced those of most OECD
nations before and during the worldwide economic recession.
Similar ongoing development characterizes another group,
identified by Goldman-Sachs’ as the “Next Eleven.” Profound
changes with deep and lasting impact to the global demand for
and provision of healthcare services and associated expenditure
have occurred. Rapid expansion of civil middle class in most of
these societies has been a major underlying factor (Jakovljevic,
2015). Substantial gains in overall welfare are reflected in the
expansion of health insurance coverage and diversity of medical
services provided. Growth of purchasing power effectively
improved affordability of advanced medical care that remains
out-of-pocket expense. We witness continuing movement of
global growth in health care markets from the established
mature economies toward the emerging ones. Slower economic
growth in most saturated high-income markets is a contributing
factor. Consumer demand for medical services remains larger in
traditional wealthy countries, but their share has been decreasing
steadily for at least two decades.
Total amount of health care spending among BRICS and
Next-11 nations became approximately six fold stronger since
1995. Share of Global Health Spending (million current US$) of
these emerging nations grew almost two and a half times. This
pace of development is far faster compared to that of vastmajority
of remaining low and middle income countries across the globe.
If we observe per capita health spending it appears that general
government expenditure on health and private expenditure is
consistently stronger among BRICS compared to N-11. Such a
historical trend was actually present prior to 1990s and spending
differentials continued to exist as paths diverted even further in
recent years. Out-of-pocket (OOP) expenditure on health is a
significant outlier in this regard. Although both country group
averages were similar at the start, N-11 OOP spending soon
exceeded BRICs. These facts indicate better success rates among
the BRICs in terms of reimbursement policies and insurance
coverage over the past 20 years (Jakovljevic, 2014).
PROSPECTS FOR THE FUTURE
Observation of health spending trends over 20 years is still
insufficient to understand a “medical transformation” taking
place in major national health systems worldwide. Limitations to
our judgment might be imposed by reliability and comparability
of large international datasets as well (Rayne, 2013). Nevertheless
contemporary transformation of global health spending lays
grounds for some forecasts on likely scenarios for the future.
Low and middle income countries are likely to become more
relevant contributor to the global health care market in the long
run. Minor proportion of these countries will likely become
high income economies over the next decade. Vast majority of
them will continue to experience serious obstacles to the fiscal
feasibility of their national health systems. Crucial challenges
will remain population aging, prosperity disease and rapid
urbanization leaving vulnerable rural areas. Universal health
insurance coverage will still be a distant policy target for most
of these governments with the notable exception of Russian
Federation (Jakovljevic et al., in press). Large out of pocket
expenses and informal payments will leave ordinary citizens,
living close to the poverty line, vulnerable to the illness-induced
catastrophic household expenditure (McIntyre et al., 2006). In
some world regions with still young populations, communicable
diseases control and satisfactory maternal and neonatal medical
care provision shall still be a long way ahead (Barik and
Thorat, 2015). Regardless of all the aforementioned weaknesses
of developing world regions, it appears that most successful
among these nations will become even more important players
in global health arena. Heavily domination of People’s Republic
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TABLE 1 | Transformation of Global Total Health Expenditure (THE) 1995–2013.
Top tier emerging
markets (BRICS +
Next-11)
Low and middle income
countries as of 1995
Low and middle income
countries as of 2013
WORLD (total amount
of all national THE)
Total number of countries observed in
1995 and 2013*, **
16 160 137 192
Share of global health spending %
(million constant 2005 $US)
1995 N/A**** 10.7 7.0 ≈100
2013 N/A**** 19.5 14.6 ≈100
Share of global health spending %
(million current US$)
1995 7.1 11.8 8.5 ≈100
2013 17.9 24.5 19.3 ≈100
Share of global health spending %
(million current PPP international $US)
1995 16.2 26.1 20.3 ≈100
2013 26.2 39.7 32.7 ≈100
THE (% of GDP)M ± SD (Min-Max) 1995 4.2 ± 1.4 (2.0–7.4) 5.5 ± 2.4 (2.0–15.8) 5.4 ± 2.4 (2.0–5.8) 5.7 ± 2.4 (2.0–15.8)
2013 5.6 ± 2.0 (2.8–9.7) 6.4 ± 2.6 (1.3–19.7) 6.4 ± 2.7(1.3–19.7) 6.8 ± 2.9 (1.3–19.7)
THE (% of GDP) percentage point
increase 1995–2013
33.3% 16.4% 18.5% 19.3%
Table based on WHO National Health Accounts data 1995–2013; Classification based on World Bank Historical Lists of Income level country groups 1995/2013 based on GNI per
capita in US$ (Atlas methodology); Top tier Emerging Markets definition adopted based on Goldman-Sachs acronyms BRICs and Next-11.
*WB Note: Income classifications are set each year on July 1 for all World Bank member economies, and all other economies with populations of more than 30,000. These official
analytical classifications are fixed during the World Bank’s fiscal year (ending on June 30), thus economies remain in the categories in which they are classified irrespective of any
revisions to their per capita income data. The historical classifications used are as published on July 1 of each fiscal year.
**Total of 13 countries/legal entities were not classified according to WB Income groups while three countries ceased to exist in 1995. In 2013 there were two of such non-classified
entities listed together with five countries that ceased to exist.
***For a total of 18 countries inclusive of Japan 2013 data are still not released officially therefore closest year available (2012 data in most cases) was used. Joint total health expenditure
of these countries excluding Japan remains significantly below 1% of global THE.
****Among the BRICS and Next–11 emerging markets THE data expressed in terms of constant 2005 $US are lacking for Russian Federation and Pakistan for the entire 19 years long
observation period and therefore inclusion of this indicator among the emerging markets was omitted entirely due to absence of data for two large nations.
of China (He and Meng, 2016) followed by India in medical
spending worldwide will exceed that of all other emerging
markets combined. As we approach 2050 it is highly likely
that financing of health care in top tier emerging nations will
converge toward OECD average in terms of its effectiveness and
affordability of medical care to the ordinary citizen (Jakovljevic,
2016). Major imperatives for national policy makers shall remain
how to achieve universal health coverage, what services would
be covered by basic insurance package and at what cost. Future
research in the field should primarily be focused on key causes
of out-of-pocket medical spending growth, deepening social
gap among the rich and poor communities leading to health
inequalities and effectiveness of contemporary policies in low and
middle income countries.
DATA REPORT METHODOLOGY
Public data sources used were WHO issued Global Health
Expenditure Database relying on NHA records: http://apps.who.
int/nha/database/Select/Indicators/en and World Bank (WB)
Income Groups; Historical country classifications based on Atlas
method: http://data.worldbank.org/about/country-and-lending-
groups. Filters applied to these extensive data sources were
indicators referring to the national level and Global Total
Health Expenditure (THE) expressed in following units: million
constant 2005 $US, million current US$, million current PPP
international $US and THE percentage share of national Gross
Domestic Product available (GDP). Data were acquired based on
reported values to the WHO and WB by the national authorities
as well as independent assessments and calculations provided by
WHO andWB and officially released in respective years. Readers
are free to access and reuse these publicly available data at the
links provided above.
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